Pre-hospital Care With Intra-Nasal Ketamine for Transport (PRECINKT): A Pilot Study
Sponsored by University of Calgary
About This Study
The investigators hypothesize that intra-nasal ketamine, for analgesia of patients with moderate to severe pain in an alpine setting, will provide a clinically significant reduction in pain and provide an effective and feasible alternative to intravenous opioids. The investigators wish to know: 1. Is our study protocol feasible to study INK in a mountain, prehospital care environment? 2. What estimate can be made of recruitment rates? 3. Does studying the use of INK interfere with or delay care at Whistler/Blackcomb? 4. Is intra-nasal ketamine an effective and safe method for controlling pain in our study population and setting? 5. Does intranasal ketamine provide a clinically significant reduction in pain or do patients require additional IV narcotics for extraction? 6. Are there any significant changes in vital signs after administration of intra-nasal ketamine 7. Does the use of intra-nasal ketamine reduce time of patient extraction and transport in the alpine pre-hospital setting? 8. Are there any long term sequelae of INK at one week?
Conditions Studied
Interventions
- •Intranasal Ketamine
Eligibility
View full eligibility criteria
Inclusion Criteria: * traumatic extremity injury * age greater than 18 years old * moderate or severe pain (VNRS 5 or greater) Exclusion Criteria: * need for an intravenous catheter as judged by treating physician * pregnancy * unable to speak English * shoulder dislocations, * previous hypersensitivity, intolerance, or allergy to ketamine, * structural or functional nasal occlusion, * inability to understand the VNRS, * Glasgow Coma Scale \<15, * inability to give informed consent * history of schizophrenia